The Prostate Cancer Registry: Monitoring patterns and quality of care for men diagnosed with prostate cancer

BJU International

Volumn 111, Issue 4 B, 2013, Pages

  Evans, Sue M ^a   Millar, Jeremy L ^d   Wood, Julie M ^a   Davis, Ian D ^a   Bolton, Damien ^f   Giles, Graham G ^e   Frydenberg, Mark ^b   Frauman, Albert ^f   Costello, Antony ^g   McNeil, John J ^c  

^a MONASH UNIVERSITY   (Australia)

^b Eastern Health Clinical School ^*  (Australia)

^c MONASH UNIVERSITY   (Australia)

^d William Buckland Radiation Oncology Service   (Australia)

^e CANCER EPIDEMIOLOGY CENTRE   (Australia)

^f AUSTIN HEALTH   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

database; epidemiology; outcome assessment; population health; prostate cancer; quality indicators; quality of care; registries

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; AUSTRALIA; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MALE; MORBIDITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE;

HUMANS; MALE; MIDDLE AGED; MORBIDITY; PROSTATIC NEOPLASMS; QUALITY INDICATORS, HEALTH CARE; REGISTRIES; RISK ASSESSMENT; VICTORIA;

EID: 84875658439     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11530.x     Document Type: Article

References (43)

1. Australian Institute of Health and Welfare. Cancer in Australia: An Overview 2010. Canberra: Australian Government, 2010: Cancer series number 60 AIHW cat no CAN 56. Available at: http://www.aihw.gov.au/publications/can/56/ 12138.pdf. Accessed 19 September 2012
2. Australian Institute for Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia: An Overview, 2010. Canberra: AIHW, 2008: Cancer Series no. 60. Cat. No. CAN 56. Available at: http://www.aihw.gov.au/publication-detail/?id=6442472459. Accessed 19 September 2012
3. Glass P, Tracey E, Smetanin P, Kobak P, Pavilichev A, Bis J,. Lives at Risk for Cancer in New South Wales 2007-2036: A Health Economics Study of Cancer in New South Wales. Eveleigh: Cancer Institute NSW, 2008
4. Wilt TJ, Brawer MK, Jomes KM, et al,. Radical prostatectomy versus observation for localized prostate cancer. New England Journal of Medicine 2012; 367: 203-13
5. Arvold ND, Chen MH, Moul JW, et al,. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol 2011; 186: 91-6
6. Coory MD, Baade PD,. Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia. Med J Aust 2005; 182: 112-5
7. English D, Farrugia H, Thursfield V, Chang P, Giles GG,. Cancer Survival, Victoria 2007. Melbourne: The Cancer Council Victoria, 2007
8. Hayen A, Smith DP, Patel MI, O'Connell DL,. Patterns of surgical care for prostate cancer in NSW, 1993-2002: rural/urban and socio-economic variation. Aust NZ J Public Health 2008; 32: 417-20
9. Karakiewicz PI, Eastham JA, Graefen M, et al,. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 2005; 66: 1245-50
10. Eastham JA, Kattan MW, Riedel E, et al,. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 2003; 170: 2292-5
11. Klein EA, Bianco FJ, Serio AM, et al,. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008; 179: 2212-6
12. Leibel SA, Hanks GE, Kramer S,. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Radiat Oncol Biol 1984; 10: 401-9
13. Spencer BA, Miller DC, Litwin MS, et al,. Variations in quality of care for men with early-stage prostate cancer. J Clin Oncol 2008; 26: 3735-42
14. Cancer Epidemiology Centre. Canstat: Prostate Cancer. No 30. Anti-Carlton: Cancer Council of Victoria, 2000
15. Victorian Consolidated Legislation. Cancer Act 1958 (Principlal Act No. 6213) As Amended by Legislation (Cancer [Cancer Reporting] Act 1980 No. 9494). Melbourne: Government of Victoria, 1980
16. Tu JV, Willison DJ, Silver FL, et al,. Impracticability of informed consent in the registry of the Canadian Stroke Network. N Engl J Med 2004; 350: 1414-21
17. Australian Institute of Health and Welfare. METeOR Metadata Online Registry [Web Page]. Available at: http://meteor.aihw.gov.au/content/index. phtml/itemId/181414. Accessed 6 March 2012
18. Commission on Cancer. Facility Oncology Registry Standards (FORDS). Chicago: American College of Surgeons, 2002
19. Eyenet Sweden. Handbook for Establishing Quality Registries. Karlskrona: Eyenet Sweden, 2005
20. Australian Cancer Network Working Party on Management of Localised Prostate Cancer. Clinical Practice Guidelines: Evidence-Based Information and Recommendations for the Management of Localised Prostate Cancer. Canberra: Commonwealth of Australia, 2002
21. American Urology Association. Prostate Cancer: Guideline for the Management of Clinically Localized Prostate Cancer: 2007 update. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines. cfm. Accessed 19 September 2012
22. National Collaborating Centre for Cancer. Prostate Cancer: Diagnosis and Treatment. NICE Clinical Guideline 58. London: National Institute for Clinical Excellence (NICE), 2008
23. Spencer B, Steinberg M, Malin J, et al,. Quality-of-care indicators for early-stage prostate cancer. J Clin Oncol 2003; 21: 1928-36
24. Evans S, Lowinger J, Sprivulis P, Hagger V, Copnell B, Cameron P,. Prioritising quality indicator development across the healthcare system: identifying what to measure. Intern Med J 2009; 39: 648-54
25. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Prostate Cancer. Available at: http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp. Accessed 19 September 2012
26. Cooperberg MR, Pasta DJ, Elkin EP, et al,. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938-42
27. Lughezzani G, Budaus L, Isbarn H, et al,. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol 2010; 57: 562-8
28. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B,. User's Manual for the SF-12v2 Health Survey with A Supplement Documenting SF-12 Health Survey. Lincoln: Quality Metrics Incorporated, 2009
29. Brazier JE, Roberts J,. The estimation of a preference-based measure of health from the SF-12. Med Care 2004; 42: 851-9
30. Litwin MS, McGuigan KA,. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 1999; 17: 2882-8
31. van Andel G, Bottomley A, Fossa S, et al,. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008; 44: 2418-24
32. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ,. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920-8
33. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG,. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899-905
34. Litwin M, Hays R, Fink A, Ganz P, Leake B, Brook R,. The UCLA Prostate Cancer Index: development, reliablility, and validity of a health-related quality of life measure. Med Care 1998; 36: 1002-12
35. Jorgensen CK, Karlsmose B,. Validation of automated forms processing. A comparison of teleform with manual data entry. Comput Biol Med 1998; 28: 659-67
36. Partin AW, Yoo J, Carter HB, et al,. The use of prostate specific antigen, clinical stage and gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-4
37. Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG,. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 2011; 185: 495-500
38. Reece AC, Cooperberg MR, Carroll PR,. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol 2010; 184: 114-9
39. Reece AC, Sadetsky N, Carroll PR, Cooperberg MR,. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer 2011; 117: 283-9
40. Miller DC, Spencer B, Ritchey J, et al,. Treatment choice and quality of care for men with localized prostate cancer. Med Care 2007; 45: 401-9
41. Australian Commission on Safety and Quality in Health Care. Operating Principles and Technical Standards for Australian Clinical Quality Registries. November 2008. Available at: http://www.health.gov.au/internet/safety/ publishing.nsf/Content/B04469807019D56CCA2578A20000A302/$File/ 02- Architecture%20and%20Technical%20Standards%20for%20Australian%20Clinical%20Qual ity%20Registries%20(full%20doc)%20(PDF%20863%20KB).PDF. Accessed 19 September 2012
42. Van Hemelrijck M, Wigertz A, Sandin F, et al,. Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol 2012 [Epub ahead of print]. doi: 10.1093/ije/dys06843
43. Porten SP, Cooperberg MR, Konety BR, Carroll PR,. The example of CaPSURE: lessons learned from a national disease registry. World J Urol 2011; 29: 265-71